Raslová, K <br/><br/>
Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.  [electronic resource] 

 -  European journal of clinical pharmacology   
 - 697-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0031-6970 
<br/><br/><label>Standard No.: </label>10.1007/s002280050537  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Arteriosclerosis--genetics<br/>Clofibric Acid--analogs & derivatives<br/>DNA Damage<br/>Female<br/>Fibric Acids<br/>Humans<br/>Hypolipidemic Agents--therapeutic use<br/>Kinetics<br/>Lipoproteins--genetics<br/>Lipoproteins, HDL--blood<br/>Lipoproteins, LDL--blood<br/>Lymphocytes--drug effects<br/>Male<br/>Middle Aged<br/>Oxidation-Reduction<br/>Phenotype